Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype

Conclusion.
Performance characteristics of breast ultrasound associated with RCB vary by cancer subtype, whereas the performance characteristics of axillary ultrasound associated with RCB are consistent across cancer subtype. Breast and axillary ultrasound may be valuable in monitoring response to neoadjuvant therapy. The Oncologist 2017;22:394–401

Implications for Practice.
The differential performance characteristics of breast ultrasound by molecular subtype and the consistent performance characteristics of axillary ultrasound across molecular subtypes can have clinical utility in monitoring response to neoadjuvant therapy.

Source: The Oncologist - April 11, 2017 Category: Cancer & Oncology Authors: Candelaria, R. P., Bassett, R. L., Symmans, W. F., Ramineni, M., Moulder, S. L., Kuerer, H. M., Thompson, A. M., Yang, W. T. Tags: Breast Cancer Source Type: research